135 related articles for article (PubMed ID: 30665865)
1. Diffuse Atypical Cystic Brain Metastases in ALK+ NSCLC Treated With Whole Brain Radiation and Second-Generation ALK-Targeted Therapy.
Grubb WR; Machtay M; Dowlati A; Biswas T
Pract Radiat Oncol; 2019 Mar; 9(2):e129-e133. PubMed ID: 30665865
[No Abstract] [Full Text] [Related]
2. Alectinib versus crizotinib in treatment-naive anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer: CNS efficacy results from the ALEX study.
Gadgeel S; Peters S; Mok T; Shaw AT; Kim DW; Ou SI; Pérol M; Wrona A; Novello S; Rosell R; Zeaiter A; Liu T; Nüesch E; Balas B; Camidge DR
Ann Oncol; 2018 Nov; 29(11):2214-2222. PubMed ID: 30215676
[TBL] [Abstract][Full Text] [Related]
3. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
4. Identification of a novel HIP1-ALK fusion variant in Non-Small-Cell Lung Cancer (NSCLC) and discovery of ALK I1171 (I1171N/S) mutations in two ALK-rearranged NSCLC patients with resistance to Alectinib.
Ou SH; Klempner SJ; Greenbowe JR; Azada M; Schrock AB; Ali SM; Ross JS; Stephens PJ; Miller VA
J Thorac Oncol; 2014 Dec; 9(12):1821-5. PubMed ID: 25393796
[TBL] [Abstract][Full Text] [Related]
5. Safety and activity of alectinib against systemic disease and brain metastases in patients with crizotinib-resistant ALK-rearranged non-small-cell lung cancer (AF-002JG): results from the dose-finding portion of a phase 1/2 study.
Gadgeel SM; Gandhi L; Riely GJ; Chiappori AA; West HL; Azada MC; Morcos PN; Lee RM; Garcia L; Yu L; Boisserie F; Di Laurenzio L; Golding S; Sato J; Yokoyama S; Tanaka T; Ou SH
Lancet Oncol; 2014 Sep; 15(10):1119-28. PubMed ID: 25153538
[TBL] [Abstract][Full Text] [Related]
6. Alectinib's activity against CNS metastases from ALK-positive non-small cell lung cancer: a single institution case series.
Metro G; Lunardi G; Bennati C; Chiarini P; Sperduti I; Ricciuti B; Marcomigni L; Costa C; Crinò L; Floridi P; Gori S; Chiari R
J Neurooncol; 2016 Sep; 129(2):355-61. PubMed ID: 27324494
[TBL] [Abstract][Full Text] [Related]
7. Rapid response of brain metastases to alectinib in a patient with non-small-cell lung cancer resistant to crizotinib.
Ajimizu H; Kim YH; Mishima M
Med Oncol; 2015 Feb; 32(2):477. PubMed ID: 25556163
[TBL] [Abstract][Full Text] [Related]
8. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
Gui Q; Liu J; Li D; Xu C
World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
[TBL] [Abstract][Full Text] [Related]
9. A Case of Squamous Cell Carcinoma Harboring an EML4-ALK Rearrangement that Was Unsuccessfully Treated with the ALK Inhibitor Alectinib.
Tamiya A; Shimizu S; Atagi S
J Thorac Oncol; 2015 Aug; 10(8):e74. PubMed ID: 26200283
[No Abstract] [Full Text] [Related]
10. Management of ceritinib therapy and adverse events in patients with ALK-rearranged non-small cell lung cancer.
Califano R; Greystoke A; Lal R; Thompson J; Popat S
Lung Cancer; 2017 Sep; 111():51-58. PubMed ID: 28838397
[TBL] [Abstract][Full Text] [Related]
11. Background and rationale of the eXalt3 trial investigating X-396 in the treatment of ALK+ non-small-cell lung cancer.
Singhi EK; Horn L
Future Oncol; 2018 Aug; 14(18):1781-1787. PubMed ID: 29506392
[TBL] [Abstract][Full Text] [Related]
12. Insights into brain metastasis in patients with ALK+ lung cancer: is the brain truly a sanctuary?
Toyokawa G; Seto T; Takenoyama M; Ichinose Y
Cancer Metastasis Rev; 2015 Dec; 34(4):797-805. PubMed ID: 26342831
[TBL] [Abstract][Full Text] [Related]
13. Clinical impact of continued crizotinib administration after isolated central nervous system progression in patients with lung cancer positive for ALK rearrangement.
Takeda M; Okamoto I; Nakagawa K
J Thorac Oncol; 2013 May; 8(5):654-7. PubMed ID: 23584297
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy as an Alternative to Whole-Brain Radiotherapy in EGFR-Mutant or ALK-Positive Non-Small-Cell Lung Cancer With Brain Metastases.
Martínez P; Mak RH; Oxnard GR
JAMA Oncol; 2017 Sep; 3(9):1274-1275. PubMed ID: 28520828
[TBL] [Abstract][Full Text] [Related]
15. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
16. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
[TBL] [Abstract][Full Text] [Related]
17. [Progress of treatments in non-small cell lung cancer with brain metastases].
Ma C; Jiang R
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):309-13. PubMed ID: 22613339
[TBL] [Abstract][Full Text] [Related]
18. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
19. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
[TBL] [Abstract][Full Text] [Related]
20. Improving Treatment Options for Brain Metastases From ALK-Positive Non-Small-Cell Lung Cancer.
Wardak Z; Choy H
J Clin Oncol; 2016 Dec; 34(34):4064-4065. PubMed ID: 27863198
[No Abstract] [Full Text] [Related]
[Next] [New Search]
